Derivatives of Thiazolidinedione for anti–breast cancer applications

Presentation

Treatments against breast cancer have limitations: innate or acquired resistances, absence of targeted therapy against some tumors.

Despite the fact that thiazolidinedione anticancer properties have been demonstrated in vitro and in vivo, some of them cannot be used because of a too high hepatotoxicity.

The invention consists of the development of a very stable troglitazone derivative (TGZ), 4 times less toxic  on primary culture of hepatocytes (viability of 80% instead of 23%). Its in vitro  antiproliferative activity is 10 times higher than the one of TGZ. In vivo tests on mice are currently being performed.

Competitive advantages

• Increased efficiency against breast cancers resistant to treatments and triple negative cancers, against which no targeted therapy exists;
• Reduced side effects: hepatic toxicity reduced by 70% compared with troglitazone (TGZ).

Applications/Markets

• Anticancer treatments
  

Intellectual property

• Patents FR2986231 - WO2013110796 - US2014364465 - EP2838899
• Filled the 26/01/12 and delivered the 07/04/14 in France

Laboratory

CRAN UMR CNRS 7039

SRSMC UMR CNRS 7565

Université de Lorraine